Andrew Bellinger discusses what it takes to build new drug modalities from scratch, the bold bets and tough calls that shaped Verve’s journey, and lessons in building new companies from first-in-class science.

* Editor's note: The interview was recorded following the announcement of Verve's acquisition by Lilly, which has since been completed.